Live news related to SANOFI stock (FR0000120578): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on SANOFI mainly cover M&A activity, analyst notes et earnings publications. The stock trades at €77,19 on Euronext Paris, up 0,68% at the last update. This page lists the articles published on SANOFI stock to track the share price, company announcements and any item likely to influence market perception.
The European Commission approved on Monday the subcutaneous formulation of Sarclisa (isatuximab), a treatment for multiple myeloma by Sanofi. This app…
Sanofi and Trackmania are launching a time-limited event partnership on Friday to educate gamers about daily diabetes management. The initiative is pa…
The pharmaceutical company marks the highest increase of the Parisian flagship index while the market trends negatively. The stock is advancing as som…
Sanofi launches on Thursday Action 2026, its global share purchase plan reserved for employees, which is open to approximately 75,000 collaborators ac…
Sanofi announces the integration of Biogen into accelRare, a free pre-diagnostic tool for rare diseases co-developed with 13 Rare Disease Health Netwo…
In the mid-afternoon, the pharmaceutical company is making no progress while the Paris stock market shows significant gains. The stock continues to su…
On Thursday, the FDA granted a priority review for the approval of venglustat to treat type 3 Gaucher's disease in the United States. If approved, thi…
Sanofi shares rise by 1.77% to €76.53 mid-session, as the CAC 40 gains 0.73%. The company is among the top performers on the CAC 40 following the posi…
Sanofi announced on Monday the results of the phase 2 ElevAATe study evaluating efdoralprin alfa, an experimental treatment for patients with emphysem…
Sanofi shares fell by 1.04% to €72.46 in mid-morning trading, after hitting €71.73 during the session, marking a new six-year low. This level surpasse…
